tirzepatide vs semaglutide results Semaglutide and Tirzepatide vs Sitagliptin

Eur J Clin Pharmacol 1992, 43(6):667669

Important safety information includes a boxed warning for risk of thyroid C-cell tumors and contraindications in patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)

But unfortunately, upon closer look, we have some serious concerns with the way this study was configured

Any suspected side effects should be reported via the MHRA Yellow Card Scheme at yellowcard

Patients receiving sitagliptin with metformin immediate-release and glimepiride had significant improvements in A1C and FPG compared to patients receiving placebo with metformin immediate-release and glimepiride (Table 11), with mean reductions from baseline relative to placebo in A1C of -0.9% and in FPG of -21 mg/dL

Some people also pair semaglutide with supplements like berberine to support metabolic outcomes